Evidence map›Paper›PMID 36579444›Full record

ArticleHaematologica2023

A novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia.

Breanna N Maniaci, Jooho Chung, Pedro Sanz-Altamira, Daniel J DeAngelo, Julia E Maxson

Abstract readLetter
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Breanna N ManiaciKnight Cancer Institute, Division of Oncologic Sciences, Oregon Health and Science University, Portland, OR.
Jooho ChungDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Pedro Sanz-AltamiraDana-Farber Cancer Institute Merrimack Valley, Lawrence, MA.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Julia E MaxsonKnight Cancer Institute, Division of Oncologic Sciences, Oregon Health and Science University, Portland, OR. maxsonj@ohsu.edu.

Funding

Role of ASXL1 in normal and abnormal granulopoiesis.R01HL157147 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MAXSON, JULIA E · 2021 to 2025
$2.4M
Mechanisms of differentiation blockade in CSF3R-mutant AMLR01CA247943 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MAXSON, JULIA E · 2021 to 2025
$2.0M
The role of NCK1 in CSF3R-driven myeloproliferative neoplasmsF31HL165919 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MANIACI, BREANNA NICOLE · 2022 to 2025
$145k
NCI NIH HHS R01 CA247943NHLBI NIH HHS F31 HL165919NHLBI NIH HHS R01 HL157147
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Neutrophilic, ChronicColony-Stimulating FactorsHumansMutationReceptors, Colony-Stimulating FactorColony-Stimulating FactorsReceptors, Colony-Stimulating Factor

Identifiers

PMID36579444
PMCPMC10316240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.